Tao Sun

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic et al. · Circulation · 2017 · 494 citations · Full text

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 372 citations

Capecitabine Versus Lapatinib, Breast Oncology, Medicine +8

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 152 citations · Full text

Breast Oncology, Medicine, Pharmacology +7

Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

Min Yan, Li Bian, Xichun Hu et al. · Translational Breast Cancer Research · 2020 · 99 citations · Full text

Breast Oncology, Oncology, Placebo-controlled Phase 3 +14